CellSeed Inc. (7776.T)

JPY 408.0

(-7.69%)

Market Cap (In JPY)

14.14 Billion

Revenue (In JPY)

190.13 Million

Net Income (In JPY)

-846.53 Million

Avg. Volume

11.09 Million

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
201.0-1160.0
PE
-
EPS
-
Beta Value
1.117
ISIN
JP3423530009
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Setsuko Hashimoto Ph.D.
Employee Count
-
Website
https://www.cellseed.com
Ipo Date
2010-03-16
Details
CellSeed Inc. develops cell sheet regenerative medicines. It is involved in the research, development, and commercialization of cell-sheet regenerative medicine products, such as epithelial cell sheet for esophageal regeneration, regenerated cartilage sheet, and chondrocyte sheet for the treatment of knee osteoarthritis. The company also offers UpCell, a temperature-responsive cell cultureware for cell-sheet engineering; RepCell, a temperature-responsive cell cutureware for cell collection; and HydroCell, a low cell binding cultureware. In addition, it provides peripheral equipment, including ThermoPlate III, a heating element made by a transparent glass plate; and cellZscope, an automated cell monitoring system, as well as contract development and manufacturing services. The company was incorporated in 2001 and is headquartered in Tokyo, Japan.